Literature DB >> 25115781

Beneficial effects of growth hormone therapy for ossification defects after bone distraction in X linked hypophosphataemic rickets.

Ramón Cañete1, Javier Caballero-Villarraso2, María Aguilar-Quintero1, Fernando Vázquez-Rueda3.   

Abstract

A report on two homozygous twin girls affected by X linked hypophosphataemic rickets. They were examined due to short stature and genu varum of both tibias. They were treated with calcitriol and Joulie's solution, whereon it was observed that serum parathyroid hormone and phosphaturia decreased while phosphataemia increased. They underwent a tibial osteotomy (by means of the insertion of Kirchner needles) at 7.7 years of age for correction of genu varum and a normal consolidation was reached 1 month later. Nonetheless, height was percentile <1 after menarche, so both sisters asked for bone lengthening. Because of this, at 15 years of age femoral distraction was performed, but no bone callus was observed 14 months later. Consequently, they were treated with subcutaneous growth hormone, showing bone callus at 6 months. Finally, the external fixators were removed due to ossification in the lengthened segments. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25115781      PMCID: PMC4139572          DOI: 10.1136/bcr-2013-203069

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

Review 1.  Genetic disorders of renal phosphate transport.

Authors:  Dominique Prié; Gérard Friedlander
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

2.  GH in combination with bisphosphonate treatment in osteogenesis imperfecta.

Authors:  Franco Antoniazzi; Elena Monti; Giacomo Venturi; Roberto Franceschi; Francesco Doro; Davide Gatti; Giorgio Zamboni; Luciano Tatò
Journal:  Eur J Endocrinol       Date:  2010-06-30       Impact factor: 6.664

3.  Growth hormone injections improve bone quality in a mouse model of osteogenesis imperfecta.

Authors:  Donna King; David Jarjoura; Heather A McEwen; Michael J Askew
Journal:  J Bone Miner Res       Date:  2005-01-18       Impact factor: 6.741

Review 4.  Growth hormone and hypophosphatemic rickets.

Authors:  D M Wilson
Journal:  J Pediatr Endocrinol Metab       Date:  2000-09       Impact factor: 1.634

5.  Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion.

Authors:  M Živičnjak; D Schnabel; H Staude; G Even; M Marx; R Beetz; M Holder; H Billing; D-C Fischer; W Rabl; M Schumacher; O Hiort; D Haffner
Journal:  J Clin Endocrinol Metab       Date:  2011-10-12       Impact factor: 5.958

6.  Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets.

Authors:  G I Baroncelli; S Bertelloni; C Ceccarelli; G Saggese
Journal:  J Pediatr       Date:  2001-02       Impact factor: 4.406

7.  Metabolic control and growth during exclusive growth hormone treatment in X-linked hypophosphatemic rickets.

Authors:  Outi Makitie; Sanna Toiviainen-Salo; Eino Marttinen; Ilkka Kaitila; Etienne Sochett; Ilkka Sipila
Journal:  Horm Res       Date:  2008-01-21

8.  Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets.

Authors:  Dieter Haffner; Richard Nissel; Elke Wühl; Otto Mehls
Journal:  Pediatrics       Date:  2004-06       Impact factor: 7.124

Review 9.  Hypophosphatemia and growth.

Authors:  Fernando Santos; Rocío Fuente; Natalia Mejia; Laura Mantecon; Helena Gil-Peña; Flor A Ordoñez
Journal:  Pediatr Nephrol       Date:  2012-11-22       Impact factor: 3.714

10.  Current and emerging treatments for the management of osteogenesis imperfecta.

Authors:  Elena Monti; Monica Mottes; Paolo Fraschini; Piercarlo Brunelli; Antonella Forlino; Giacomo Venturi; Francesco Doro; Silvia Perlini; Paolo Cavarzere; Franco Antoniazzi
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423

  10 in total
  1 in total

Review 1.  Recombinant growth hormone therapy for X-linked hypophosphatemia in children.

Authors:  Sherie Smith; Tracey Remmington
Journal:  Cochrane Database Syst Rev       Date:  2021-10-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.